https://doi.org/10.4081/reumatismo.2016.911

Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment

Vol. 68 No. 3 (2016)
Published: December 16 2016
Spondylodiscitis, etanercept, ankylosing spondylitis.
Abstract Views: 3025
PDF: 779
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M. Benucci
maurizio.benucci@uslcentro.toscana.it
Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
A. Damiani
Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
A. Arena
Nuclear Medicine Unit, New Hospital, Prato, Italy.
M. Infantino
Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
M. Manfredi
Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
F. Li Gobbi
Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
We observed a 69-year old man suffering from HLA B27 ankylosing spondylitis with persistent night back pain. 18F-FDG-PET/CT showed an increased metabolism at the level of the spinal space of L2-L3, L3-L4 with increased uptake compatible with spondylodiscitis. He started therapy with etanercept 50 mg/week. After six months of treatment repeated testing showed no uptake of the discs and vertebral bodies.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
M. Benucci, Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze
Internal Medicine

How to Cite



Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment. (2016). Reumatismo, 68(3), 163-165. https://doi.org/10.4081/reumatismo.2016.911

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.